Using a similar analysis of DNA in common, TGen researchers, working with collaborators at the University of California at Los Angeles, last year developed a way to identify an individual’s DNA from a mixture of DNA from hundreds or even thousands.The study found two markers that may be associated with type 2 diabetes, the most common form of diabetes. Type 2 occurs when the body fails to produce enough insulin, which helps convert glucose from sugars and starches we eat into energy. Failure to process glucose cells starved of energy and time can damage the eyes, nerves, heart or kidneys. Type 2 diabetes can be prevented or treated with proper diet and exercise.
The results of the study, published in the December issue of medication for diabetes, show that it is possible to identify biomarkers associated with end-stage renal disease (ESRD) in the DNA pool of more than 1000 people with diabetes. In particular, researchers have identified genes that may contribute to TGen ESRD in people with type 1 diabetes.
The experiments have identified at least eight places along the human genome almost 3 billion base that is ripe for further investigation of their links with the IRT, the paper said, the study of genome-wide SNP genotyping with DNA markers in common to identify candidate mediation to end stage renal disease attributed to the susceptibility to type 1 diabetes.
TGen researchers tested the genomic DNA pool of over 500 for those with ESRD and compared it to more than 500 patients with type I diabetes for at least 20 years without any sign of the IRT. Scientists have conducted genome-wide association scan to search for single nucleotide polymorphisms (SNPs), which are the individual letters of DNA that vary among individuals. They looked for SNPs that indicate a predisposition to ESRD.
The study found at least six markers that may be associated with type 1 diabetes, a chronic disease that occurs when the pancreas does not produce enough insulin to properly control blood sugar. There is currently no way to prevent type 1, which is caused by autoimmune, genetic or environmental factors.
Nearly 24 million Americans, or about 8 percent of diabetes, according to the American Diabetes Association, which lists the disease as the seventh leading cause of death nation.
The need to quickly identify people with a predisposition to kidney failure and the discovery of new drugs to prevent and treat this devastating disease becomes crucial, as the onset of the disease affects people younger persons on average. Although type 1 diabetes is significantly different from type 2 diabetes, the development of renal disease is similar in people with both forms. The researchers plan to present the results on the impact of individuals with both forms of the disease.
Nearly 23 percent of Americans diagnosed with end stage renal disease die within the first year. And the annual cost of about 400,000 people who need blood, dialysis or kidney transplant is more than $ 16 billion.
Researchers using a DNA analysis tool developed by the Translational Genomics Research Institute (TGen) and UCLA have identified genetic markers that could help treat chronic kidney disease in diabetics.
ESRD almost always from chronic kidney failure and even if treated with dialysis or transplantation, mortality rates remain high. While diabetic nephropathy is one of the most common complications of diabetes, it is not possible to determine who is at risk of renal failure.
Diabetic nephropathy, or kidney disease, is the most common cause of ESRD. It occurs when chronic kidney disease has progressed to the point where they are needed two kidney transplants or dialysis to prevent blood poisoning.
“This technique will be used to identify the genetic origin of several types of diseases, predicted Dr”David Craig, Deputy Director of the Division of TGen neurogenomics, who co-developed the technique and was the principal author of this study.
“The identification of specific DNA variants may enhance our understanding of genetic risk factors for kidney disease and may provide a diagnostic value to determine which patients are at increased risk of developing end-stage renal disease,” said Dr. Johanna DiStefano, Director of TGen diabetes, cardiovascular disease and metabolic Division and lead author of the study.